Physician profile
Daniel E Kosobucki
NPI 1881775518
$6,398.54
in general payments reported to CMS, 2019-2025
40 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $1,451 · 2021: $1,678 · 2022: $1,097 · 2023: $653 · 2024: $316 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,305.46 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $943.95 | 2020-2025 | |
| Glaxosmithkline, LLC. | $459.42 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $368.60 | 2019-2025 | |
| Allergan, INC. | $363.85 | 2019-2020 | |
| Astellas Pharma US INC | $317.17 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.53 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $264.32 | 2019-2022 | |
| Esperion Therapeutics, INC. | $247.54 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $166.89 | 2019-2022 | |
| Amgen INC. | $155.58 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $128.61 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $120.93 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $109.48 | 2019-2022 | |
| Pfizer INC. | $106.02 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kosobucki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.